Gemcitabine Plus Sorafenib Not More Effective Than Gemcitabine Alone for Advanced Biliary Tract Cancer
the Cancer Therapy Advisor take:
According to a new study published in the European Journal of Cancer, researchers have found that the addition of sorafenib to gemcitabine for the treatment of patients with advanced biliary tract cancer is not more effective than gemcitabine alone. For the phase 2 study, researchers enrolled 102 patients with unresectable or metastatic biliary tract cancer.
Patients were randomly assigned to receive gemcitabine 1,000mg/m2 once weekly for the first 7 weeks with 1 week of rest followed by once weekly for 3 weeks and 1 week of rest, plus sorafenib 400mg twice daily or placebo. Patients were treated until disease progression or unacceptable toxicity.
Results showed that patients tolerated the combination well. Four patients achieved partial responses in the sorafenib group and three patients achieved partial responses in the placebo group. The researchers found no difference in median progression-free survival between the two group (3.0 months for sorafenib vs 4.9 months placebo, P = 0.859).
In addition, there was no difference in overall survival between sorafenib and placebo (8.4 months vs 11.2 months, P = 0.775). Patients with liver metastases after surgery to remove primary biliary tract cancer survived longer with sorafenib compared with placebo (P = 0.019).
Sorafenib with gemcitabine for the treatment advanced biliary tract cancer is not more effective than gemcitabine alone.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer